A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Infectious Diseases - Tập 12 - Trang 290-299 - 2012
Mohamed A Kharfan-Dabaja1,2, Michael Boeckh3, Marissa B Wilck4,5, Amelia A Langston6, Alice H Chu7, Mary K Wloch8, Don F Guterwill7, Larry R Smith8, Alain P Rolland9, Richard T Kenney7
1Department of Blood and Marrow Transplantation and Department of Oncological Sciences, H Lee Moffitt Cancer Center and Research Institute and University of South Florida, Tampa, FL, USA
2American University of Beirut Medical Center, Division of Hematology-Oncology and Bone Marrow Transplantation, Beirut, Lebanon
3Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA;
4Division of Infectious Diseases, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston MA, USA
5Division of Infectious Diseases, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
6Bone Marrow and Stem Cell Transplant Center, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
7Department of Clinical Development, Vical, San Diego, CA, USA
8Department of Vaccinology, Vical, San Diego, CA, USA
9Department of Product Development, Vical, San Diego, CA, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Infectious Diseases

Tập 12

290-299

Thông tin tác giả